{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,24]],"date-time":"2026-03-24T09:04:09Z","timestamp":1774343049868,"version":"3.50.1"},"reference-count":47,"publisher":"MDPI AG","issue":"2","license":[{"start":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T00:00:00Z","timestamp":1651017600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Neurology International"],"abstract":"<jats:p>Background and aims. Patients with Myasthenia gravis (MG) are considered vulnerable as they may present with respiratory muscle weakness and because they are on immunosuppressive treatment; thereby, COVID-19 may have a detrimental effect on these patients. Vaccines against COVID-19 are currently available and it has been shown as they can prevent severe COVID-19 in vulnerable patients. Notwithstanding their efficacy, vaccine hesitancy has not been completely dispelled in the general population. Unfortunately, there is limited data about the safety of these vaccines in MG patients. The aims of this study are to evaluate the impact of COVID-19 in a MG cohort, the adherence to COVID-19 vaccination in Italy and vaccine safety in MG patients. Methods. A retrospective cohort study of MG patients attending the Neuromuscular Clinic of the University Hospital \u201cPaolo Giaccone\u201d of Palermo, Italy, was performed. Patients underwent telephone interviews with a dedicated questionnaire on SARS-CoV-2 vaccination and infection. Vaccine safety was assessed though the evaluation of vaccine-related adverse events (AEs) and comparisons of MG-ADL scores before and after vaccination. Patient worsening was defined as two or more point increases in MG-ADL scores. Results. From a total of 90 participants, 75 answered the questionnaire and 70.5% of them (n = 53) received the vaccine; ten patients did not receive vaccination and 3 patients were partially vaccinated. Among the vaccinated patients, about 45% (n = 24) experienced at least one AE, with a complete resolution within one week. No serious AEs and life-threatening conditions were observed. Globally, MG-ADL scores did not worsen after vaccination. Nine unvaccinated patients experienced SARS-CoV2 infection and four of them (44%) died\u2014one patient required respiratory support, whereas three patients were asymptomatic. Conclusions. COVID-19 significantly impacted MG patients with an increase in mortality due to respiratory sequelae. Vaccines against SARS-CoV-2 showed good short-term safety in MG patients, who may take advantage of vaccination to avoiding life-threatening complications such as COVID-19 pneumonia.<\/jats:p>","DOI":"10.3390\/neurolint14020033","type":"journal-article","created":{"date-parts":[[2022,4,27]],"date-time":"2022-04-27T22:20:20Z","timestamp":1651098020000},"page":"406-416","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":39,"title":["Impact of COVID-19 in AChR Myasthenia Gravis and the Safety of Vaccines: Data from an Italian Cohort"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-1499-9460","authenticated-orcid":false,"given":"Antonino","family":"Lupica","sequence":"first","affiliation":[{"name":"Section of Neurology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BIND), University of Palermo, 9012 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9805-1655","authenticated-orcid":false,"given":"Vincenzo","family":"Di Stefano","sequence":"additional","affiliation":[{"name":"Section of Neurology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BIND), University of Palermo, 9012 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0035-5859","authenticated-orcid":false,"given":"Salvatore","family":"Iacono","sequence":"additional","affiliation":[{"name":"Section of Neurology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BIND), University of Palermo, 9012 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8883-5701","authenticated-orcid":false,"given":"Antonia","family":"Pignolo","sequence":"additional","affiliation":[{"name":"Section of Neurology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BIND), University of Palermo, 9012 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Martina","family":"Quartana","sequence":"additional","affiliation":[{"name":"Section of Neurology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BIND), University of Palermo, 9012 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Gagliardo","sequence":"additional","affiliation":[{"name":"Section of Neurology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BIND), University of Palermo, 9012 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Brigida","family":"Fierro","sequence":"additional","affiliation":[{"name":"Section of Neurology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BIND), University of Palermo, 9012 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Filippo","family":"Brighina","sequence":"additional","affiliation":[{"name":"Section of Neurology, Department of Biomedicine, Neuroscience and Advanced Diagnostics (BIND), University of Palermo, 9012 Palermo, Italy"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1968","published-online":{"date-parts":[[2022,4,27]]},"reference":[{"key":"ref_1","doi-asserted-by":"crossref","first-page":"428","DOI":"10.1111\/ane.13071","article-title":"Autoantibodies in acquired myasthenia gravis: Clinical phenotype and immunological correlation","volume":"139","author":"Nagappa","year":"2019","journal-title":"Acta Neurol. Scand."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"176","DOI":"10.17712\/nsj.2019.3.20190011","article-title":"Clinical features and outcomes of patients with myasthenia gravis","volume":"24","author":"Alanazy","year":"2019","journal-title":"Neurosciences"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"909","DOI":"10.1002\/mus.23330","article-title":"Recommendations for myasthenia gravis clinical trials","volume":"45","author":"Benatar","year":"2012","journal-title":"Muscle Nerve"},{"key":"ref_4","first-page":"e2109","article-title":"Impact of Coronavirus Disease 2019 in a French Cohort of Myasthenia Gravis","volume":"96","author":"Mathis","year":"2021","journal-title":"Neurology"},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"970","DOI":"10.1016\/S1474-4422(20)30413-0","article-title":"COVID-19-associated risks and effects in myasthenia gravis (CARE-MG)","volume":"19","author":"Muppidi","year":"2020","journal-title":"Lancet Neurol."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"633","DOI":"10.1007\/s13760-021-01612-6","article-title":"Myasthenia gravis at the crossroad of COVID-19: Focus on immunological and respiratory interplay","volume":"121","author":"Galassi","year":"2021","journal-title":"Acta Neurol. Belg."},{"key":"ref_7","first-page":"20","article-title":"Significant reduction of physical activity in patients with neuromuscular disease during COVID-19 pandemic: The long-term consequences of quarantine","volume":"268","author":"Battaglia","year":"2020","journal-title":"J. Neurol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"1580","DOI":"10.1007\/s00415-020-10149-2","article-title":"Management of patients with neuromuscular disorders at the time of the SARS-CoV-2 pandemic","volume":"268","author":"Costamagna","year":"2021","journal-title":"J. Neurol."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"125","DOI":"10.4081\/reumatismo.2015.849","article-title":"Myasthenia gravis due to hydroxychloroquine","volume":"67","author":"Varan","year":"2015","journal-title":"Reumatismo"},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"110166","DOI":"10.1016\/j.jclinane.2021.110166","article-title":"Does the virus or the doctor promote myasthenic crises in COVID-19 patients with myasthenia?","volume":"70","author":"Finsterer","year":"2021","journal-title":"J. Clin. Anesth."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"100332","DOI":"10.1016\/j.ensci.2021.100332","article-title":"Case series: COVID-19 in patients with mild to moderate myasthenia gravis in a National Referral Hospital in Indonesia","volume":"23","author":"Octaviana","year":"2021","journal-title":"eNeurologicalSci"},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"507","DOI":"10.1016\/j.neurol.2020.04.004","article-title":"Guidance for the care of neuromuscular patients during the COVID-19 pandemic outbreak from the French Rare Health Care for Neuromuscular Diseases Network","volume":"176","author":"Pereon","year":"2020","journal-title":"Rev. Neurol."},{"key":"ref_13","doi-asserted-by":"crossref","unstructured":"Lo Sasso, B., Giglio, R.V., Vidali, M., Scazzone, C., Bivona, G., Gambino, C.M., Maria, C.A., Luisa, A., and Marcello, C. (2021). Evaluation of Anti-SARS-CoV-2 S-RBD IgG Antibodies after COVID-19 mRNA BNT162b2 Vaccine. Diagnostics, 11.","DOI":"10.3390\/diagnostics11071135"},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"294","DOI":"10.1002\/mus.27179","article-title":"Doctor\u2014Should I get the COVID-19 vaccine? Infection and immunization in individuals with neuromuscular disorders","volume":"63","author":"Gruener","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"102792","DOI":"10.1016\/j.autrev.2021.102792","article-title":"The SARS-CoV-2 as an instrumental trigger of autoimmunity","volume":"20","author":"Dotan","year":"2021","journal-title":"Autoimmun. Rev."},{"key":"ref_16","doi-asserted-by":"crossref","unstructured":"Watad, A., De Marco, G., Mahajna, H., Druyan, A., Eltity, M., Hijazi, N., Haddad, A., Elias, M., Zisman, D., and Naffaa, M.E. (2021). Immune-mediated disease flares or new-onset disease in 27 subjects following mrna\/dna SARS-CoV-2 vaccination. Vaccines, 9.","DOI":"10.3390\/vaccines9050435"},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"1097","DOI":"10.1172\/JCI200114235","article-title":"Mechanisms for the induction of autoimmunity by infectious agents","volume":"108","author":"Wucherpfennig","year":"2001","journal-title":"J. Clin. Investig."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"525","DOI":"10.1097\/BOR.0000000000000630","article-title":"Infections as triggers of flares in systemic autoimmune diseases: Novel innate immunity mechanisms","volume":"31","year":"2019","journal-title":"Curr. Opin. Rheumatol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"880","DOI":"10.1016\/j.autrev.2015.05.014","article-title":"On vaccine\u2019s adjuvants and autoimmunity: Current evidence and future perspectives","volume":"14","author":"Pellegrino","year":"2015","journal-title":"Autoimmun. Rev."},{"key":"ref_20","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1016\/j.morpho.2016.01.002","article-title":"Aluminum adjuvants of vaccines injected into the muscle: Normal fate, pathology and associated disease","volume":"100","author":"Gherardi","year":"2016","journal-title":"Morphologie"},{"key":"ref_21","doi-asserted-by":"crossref","first-page":"361","DOI":"10.1586\/eci.13.2","article-title":"Autoimmune\/inflammatory syndrome induced by adjuvants (Shoenfeld\u2019s syndrome): Clinical and immunological spectrum","volume":"9","author":"Medina","year":"2013","journal-title":"Expert Rev. Clin. Immunol."},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"129","DOI":"10.1007\/978-3-540-72167-3_7","article-title":"Nucleic acid recognition receptors in autoimmunity","volume":"183","author":"Krug","year":"2008","journal-title":"Handb. Exp. Pharmacol."},{"key":"ref_23","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1038\/s41577-021-00526-x","article-title":"COVID-19 vaccines: Modes of immune activation and future challenges","volume":"21","author":"Teijaro","year":"2021","journal-title":"Nat. Rev. Immunol."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1159\/000494034","article-title":"Extracellular RNA Sensing by Pattern Recognition Receptors","volume":"10","author":"Tatematsu","year":"2018","journal-title":"J. Innate Immun."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"2527","DOI":"10.1084\/jem.20161596","article-title":"Type I interferon-mediated monogenic autoinflammation: The type I interferonopathies, a conceptual overview","volume":"213","author":"Rodero","year":"2016","journal-title":"J. Exp. Med."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2","DOI":"10.3899\/jrheum.091461","article-title":"Epidemiology of immune-mediated inflammatory diseases: Incidence, prevalence, natural history, and comorbidities","volume":"85","author":"Guenther","year":"2010","journal-title":"J. Rheumatol. Suppl."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1007\/s10072-019-03746-1","article-title":"Italian recommendations for the diagnosis and treatment of myasthenia gravis","volume":"40","author":"Evoli","year":"2019","journal-title":"Neurol. Sci."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"26","DOI":"10.1111\/ane.12233","article-title":"Myasthenia gravis epidemiology in a national cohort; combining multiple disease registries","volume":"129","author":"Andersen","year":"2014","journal-title":"Acta Neurol. Scand."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"451","DOI":"10.1038\/s41577-020-0372-8","article-title":"Optimizing safety surveillance for COVID-19 vaccines","volume":"20","author":"Chandler","year":"2020","journal-title":"Nat. Rev. Immunol."},{"key":"ref_30","doi-asserted-by":"crossref","first-page":"1487","DOI":"10.1212\/WNL.52.7.1487","article-title":"Myasthenia gravis activities of daily living profile","volume":"52","author":"Wolfe","year":"1999","journal-title":"Neurology"},{"key":"ref_31","doi-asserted-by":"crossref","first-page":"727","DOI":"10.1002\/mus.22140","article-title":"MG-ADL: Still a relevant outcome measure","volume":"44","author":"Muppidi","year":"2011","journal-title":"Muscle Nerve"},{"key":"ref_32","doi-asserted-by":"crossref","first-page":"1927","DOI":"10.1007\/s10072-017-3083-6","article-title":"Validity, reliability, and sensitivity to change of the myasthenia gravis activities of daily living profile in a sample of Italian myasthenic patients","volume":"38","author":"Raggi","year":"2017","journal-title":"Neurol. Sci."},{"key":"ref_33","doi-asserted-by":"crossref","first-page":"206","DOI":"10.1002\/mus.27324","article-title":"COVID-19 in patients with myasthenia gravis: Epidemiology and disease course","volume":"64","author":"Businaro","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref_34","first-page":"61","article-title":"COVID-19 pandemic year in a sample of Polish myasthenia gravis patients: An observational study","volume":"56","year":"2021","journal-title":"Neurol. Neurochir. Pol."},{"key":"ref_35","doi-asserted-by":"crossref","first-page":"254","DOI":"10.1002\/mus.26918","article-title":"COVID-19 in patients with myasthenia gravis","volume":"62","author":"Anand","year":"2020","journal-title":"Muscle Nerve"},{"key":"ref_36","doi-asserted-by":"crossref","first-page":"1053","DOI":"10.3389\/fneur.2020.01053","article-title":"Myasthenia Gravis and COVID-19: Clinical Characteristics and Outcomes","volume":"11","author":"Silva","year":"2020","journal-title":"Front. Neurol."},{"key":"ref_37","doi-asserted-by":"crossref","first-page":"1039","DOI":"10.1007\/s13760-021-01662-w","article-title":"Case series of COVID-19 in patients with myasthenia gravis: A single institution experience","volume":"121","author":"Majdak","year":"2021","journal-title":"Acta Neurol. Belg."},{"key":"ref_38","doi-asserted-by":"crossref","first-page":"117053","DOI":"10.1016\/j.jns.2020.117053","article-title":"Description of 3 patients with myasthenia gravis and COVID-19","volume":"417","author":"Rein","year":"2020","journal-title":"J. Neurol. Sci."},{"key":"ref_39","doi-asserted-by":"crossref","first-page":"334","DOI":"10.1111\/ane.13440","article-title":"Ben Myasthenia gravis and COVID-19: A case series and comparison with literature","volume":"144","author":"Saied","year":"2021","journal-title":"Acta Neurol. Scand."},{"key":"ref_40","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1016\/j.neurol.2020.03.002","article-title":"COVID-19, the pandemic war: Implication for neurologists","volume":"176","year":"2020","journal-title":"Rev. Neurol."},{"key":"ref_41","doi-asserted-by":"crossref","first-page":"106488","DOI":"10.1016\/j.clineuro.2021.106488","article-title":"Impact of COVID-19 pandemic and lockdown in a cohort of myasthenia gravis patients in India","volume":"202","author":"Kalita","year":"2021","journal-title":"Clin. Neurol. Neurosurg."},{"key":"ref_42","doi-asserted-by":"crossref","first-page":"4889","DOI":"10.1007\/s10072-021-05566-8","article-title":"Myasthenia gravis and telemedicine: A lesson from COVID-19 pandemic","volume":"42","author":"Ricciardi","year":"2021","journal-title":"Neurol. Sci."},{"key":"ref_43","doi-asserted-by":"crossref","first-page":"831","DOI":"10.1002\/mus.27243","article-title":"Telephone consultation for myasthenia gravis care during the COVID-19 pandemic: Assessment of a novel virtual myasthenia gravis index","volume":"63","author":"Menon","year":"2021","journal-title":"Muscle Nerve"},{"key":"ref_44","doi-asserted-by":"crossref","first-page":"2603","DOI":"10.1056\/NEJMoa2034577","article-title":"Safety and Efficacy of the BNT162b2 mRNA COVID-19 Vaccine","volume":"383","author":"Polack","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"ref_45","doi-asserted-by":"crossref","first-page":"403","DOI":"10.1056\/NEJMoa2035389","article-title":"Efficacy and Safety of the mRNA-1273 SARS-CoV-2 Vaccine","volume":"384","author":"Baden","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"ref_46","doi-asserted-by":"crossref","first-page":"467","DOI":"10.1016\/S0140-6736(20)31604-4","article-title":"Safety and immunogenicity of the ChAdOx1 nCoV-19 vaccine against SARS-CoV-2: A preliminary report of a phase 1\/2, single-blind, randomised controlled trial","volume":"396","author":"Folegatti","year":"2020","journal-title":"Lancet"},{"key":"ref_47","doi-asserted-by":"crossref","first-page":"99","DOI":"10.1016\/S0140-6736(20)32661-1","article-title":"Safety and efficacy of the ChAdOx1 nCoV-19 vaccine (AZD1222) against SARS-CoV-2: An interim analysis of four randomised controlled trials in Brazil, South Africa, and the UK","volume":"397","author":"Voysey","year":"2021","journal-title":"Lancet"}],"container-title":["Neurology International"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/2035-8377\/14\/2\/33\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T23:02:14Z","timestamp":1760137334000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/2035-8377\/14\/2\/33"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,4,27]]},"references-count":47,"journal-issue":{"issue":"2","published-online":{"date-parts":[[2022,6]]}},"alternative-id":["neurolint14020033"],"URL":"https:\/\/doi.org\/10.3390\/neurolint14020033","relation":{},"ISSN":["2035-8377"],"issn-type":[{"value":"2035-8377","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,4,27]]}}}